Author/Authors :
Ali, Azka Department of Internal Medicine - University of Florida - Gainesville - FL, USA , IV, William Paul Skelton Department of Internal Medicine - University of Florida - Gainesville - FL, USA , Akhavan, Neeka N. Department of Internal Medicine - University of Florida - Gainesville - FL, USA , Taylor, Zachary A. Department of Internal Medicine - University of Florida - Gainesville - FL, USA , Nguyen, Thu-Cuc Department of Internal Medicine - University of Central Florida - Orlando - FL, USA , Hassan, Hassan Cancer Specialists of North Florida - Saint Augustine - FL, USA , Townsend, Tabitha N. Division of Hematology and Oncology - Department of Internal Medicine - University of Florida - Gainesville - FL, USA , Pathak, Prajwol Division of Hematology and Oncology - Department of Internal Medicine - University of Florida - Gainesville - FL, USA , Trikha, Gaurav Division of Hematology and Oncology - Department of Internal Medicine - University of Florida - Gainesville - FL, USA , Dang, Nam H. Division of Hematology and Oncology - Department of Internal Medicine - University of Florida - Gainesville - FL, USA , Dang, Long H. Division of Hematology and Oncology - Department of Internal Medicine - University of Florida - Gainesville - FL, USA
Abstract :
Ibrutinib is commonly used for the treatment of patients with CLL in either first-line or relapsed/refractory settings.Case Presentation. We present the case of a 74-year-old Caucasian man with CLL who presented with penile gangrene upon initiationof ibrutinib treatment. Our case is the first showing the complication of penile gangrene associated with ibrutinib use. The gangrenewas self-limited upon discontinuing ibrutinib.Conclusion. Our finding describes a very rare yet important adverse event associatedwith ibrutinib use.
Keywords :
Penile Gangrene , Patient , Treated , Ibrutinib , Chronic Lymphocytic Leukemia , Chronic lymphocytic leukemia (CLL)
